257 related articles for article (PubMed ID: 18367253)
1. Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer's disease.
Bermejo P; Martín-Aragón S; Benedí J; Susín C; Felici E; Gil P; Ribera JM; Villar AM
Immunol Lett; 2008 May; 117(2):198-202. PubMed ID: 18367253
[TBL] [Abstract][Full Text] [Related]
2. Plasma aminothiol compounds, but not serum tumor necrosis factor receptor II and soluble receptor for advanced glycation end products, are related to the cognitive impairment in Alzheimer's disease and mild cognitive impairment patients.
Hernanz A; De la Fuente M; Navarro M; Frank A
Neuroimmunomodulation; 2007; 14(3-4):163-7. PubMed ID: 18073509
[TBL] [Abstract][Full Text] [Related]
3. Higher serum sTNFR1 level predicts conversion from mild cognitive impairment to Alzheimer's disease.
Diniz BS; Teixeira AL; Ojopi EB; Talib LL; Mendonça VA; Gattaz WF; Forlenza OV
J Alzheimers Dis; 2010; 22(4):1305-11. PubMed ID: 20930310
[TBL] [Abstract][Full Text] [Related]
4. Macrophage migration inhibitory factor in mild cognitive impairment and Alzheimer's disease.
Popp J; Bacher M; Kölsch H; Noelker C; Deuster O; Dodel R; Jessen F
J Psychiatr Res; 2009 May; 43(8):749-53. PubMed ID: 19038405
[TBL] [Abstract][Full Text] [Related]
5. Peripheral levels of glutathione and protein oxidation as markers in the development of Alzheimer's disease from Mild Cognitive Impairment.
Bermejo P; Martín-Aragón S; Benedí J; Susín C; Felici E; Gil P; Ribera JM; Villar AM
Free Radic Res; 2008 Feb; 42(2):162-70. PubMed ID: 18297609
[TBL] [Abstract][Full Text] [Related]
6. Changes of some oxidative stress markers in the serum of patients with mild cognitive impairment and Alzheimer's disease.
Padurariu M; Ciobica A; Hritcu L; Stoica B; Bild W; Stefanescu C
Neurosci Lett; 2010 Jan; 469(1):6-10. PubMed ID: 19914330
[TBL] [Abstract][Full Text] [Related]
7. Plasma beta amyloid and cytokine profile in women with Alzheimer's disease.
Baranowska-Bik A; Bik W; Wolinska-Witort E; Martynska L; Chmielowska M; Barcikowska M; Baranowska B
Neuro Endocrinol Lett; 2008 Feb; 29(1):75-9. PubMed ID: 18283248
[TBL] [Abstract][Full Text] [Related]
8. Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease.
Galimberti D; Schoonenboom N; Scheltens P; Fenoglio C; Bouwman F; Venturelli E; Guidi I; Blankenstein MA; Bresolin N; Scarpini E
Arch Neurol; 2006 Apr; 63(4):538-43. PubMed ID: 16606766
[TBL] [Abstract][Full Text] [Related]
9. Quantitative EEG in progressing vs stable mild cognitive impairment (MCI): results of a 1-year follow-up study.
Luckhaus C; Grass-Kapanke B; Blaeser I; Ihl R; Supprian T; Winterer G; Zielasek J; Brinkmeyer J
Int J Geriatr Psychiatry; 2008 Nov; 23(11):1148-55. PubMed ID: 18537220
[TBL] [Abstract][Full Text] [Related]
10. Both plasma retinol-binding protein and haptoglobin precursor allele 1 in CSF: candidate biomarkers for the progression of normal to mild cognitive impairment to Alzheimer's disease.
Jung SM; Lee K; Lee JW; Namkoong H; Kim HK; Kim S; Na HR; Ha SA; Kim JR; Ko J; Kim JW
Neurosci Lett; 2008 May; 436(2):153-7. PubMed ID: 18378077
[TBL] [Abstract][Full Text] [Related]
11. Changes in the levels of plasma soluble fractalkine in patients with mild cognitive impairment and Alzheimer's disease.
Kim TS; Lim HK; Lee JY; Kim DJ; Park S; Lee C; Lee CU
Neurosci Lett; 2008 May; 436(2):196-200. PubMed ID: 18378084
[TBL] [Abstract][Full Text] [Related]
12. Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease.
Galimberti D; Fenoglio C; Lovati C; Venturelli E; Guidi I; Corrà B; Scalabrini D; Clerici F; Mariani C; Bresolin N; Scarpini E
Neurobiol Aging; 2006 Dec; 27(12):1763-8. PubMed ID: 16307829
[TBL] [Abstract][Full Text] [Related]
13. Soluble interleukin-1 receptor type II, IL-18 and caspase-1 in mild cognitive impairment and severe Alzheimer's disease.
Lindberg C; Chromek M; Ahrengart L; Brauner A; Schultzberg M; Garlind A
Neurochem Int; 2005 Jun; 46(7):551-7. PubMed ID: 15843049
[TBL] [Abstract][Full Text] [Related]
14. Serum TNF-alpha levels are increased and correlate negatively with free IGF-I in Alzheimer disease.
Alvarez A; Cacabelos R; Sanpedro C; García-Fantini M; Aleixandre M
Neurobiol Aging; 2007 Apr; 28(4):533-6. PubMed ID: 16569464
[TBL] [Abstract][Full Text] [Related]
15. Systemic immune aberrations in Alzheimer's disease patients.
Bonotis K; Krikki E; Holeva V; Aggouridaki C; Costa V; Baloyannis S
J Neuroimmunol; 2008 Jan; 193(1-2):183-7. PubMed ID: 18037502
[TBL] [Abstract][Full Text] [Related]
16. [Serum levels of macrophage colony stimulating factor in the patients with Alzheimer's disease].
Kong QL; Zhang JM; Zhang ZX; Ge PJ; Xu YJ; Mi RS; Zhao YH; Sui YP; He W
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2002 Jun; 24(3):298-301. PubMed ID: 12905639
[TBL] [Abstract][Full Text] [Related]
17. White-matter vascular lesions correlate with alpha EEG sources in mild cognitive impairment.
Babiloni C; Frisoni GB; Pievani M; Toscano L; Del Percio C; Geroldi C; Eusebi F; Miniussi C; Rossini PM
Neuropsychologia; 2008; 46(6):1707-20. PubMed ID: 18440574
[TBL] [Abstract][Full Text] [Related]
18. Altered plasma cytokine levels in Alzheimer's disease: correlation with the disease progression.
Motta M; Imbesi R; Di Rosa M; Stivala F; Malaguarnera L
Immunol Lett; 2007 Nov; 114(1):46-51. PubMed ID: 17949824
[TBL] [Abstract][Full Text] [Related]
19. Cytokines in Alzheimer's disease and vascular dementia.
Angelopoulos P; Agouridaki H; Vaiopoulos H; Siskou E; Doutsou K; Costa V; Baloyiannis SI
Int J Neurosci; 2008 Dec; 118(12):1659-72. PubMed ID: 18937113
[TBL] [Abstract][Full Text] [Related]
20. Bioplex analysis of plasma cytokines in Alzheimer's disease and mild cognitive impairment.
Lee KS; Chung JH; Lee KH; Shin MJ; Oh BH; Hong CH
Immunol Lett; 2008 Dec; 121(2):105-9. PubMed ID: 18930766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
